C

Chromocell Therapeutics Corp
AMEX:CHRO

Watchlist Manager
Chromocell Therapeutics Corp
AMEX:CHRO
Watchlist
Price: 22.46 USD -5.03% Market Closed
Market Cap: 3.8m USD

Chromocell Therapeutics Corp
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Chromocell Therapeutics Corp
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
C
Chromocell Therapeutics Corp
AMEX:CHRO
EPS (Diluted)
-$1
CAGR 3-Years
-127%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

Chromocell Therapeutics Corp
Glance View

Market Cap
3.8m USD
Industry
Biotechnology

Chromocell Therapeutics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in North Brunswick, New Jersey and currently employs 3 full-time employees. The company went IPO on 2024-02-16. Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.

CHRO Intrinsic Value
Not Available
C

See Also

What is Chromocell Therapeutics Corp's EPS (Diluted)?
EPS (Diluted)
-1.3 USD

Based on the financial report for Dec 31, 2023, Chromocell Therapeutics Corp's EPS (Diluted) amounts to -1.3 USD.

What is Chromocell Therapeutics Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-127%

Over the last year, the EPS (Diluted) growth was -198%. The average annual EPS (Diluted) growth rates for Chromocell Therapeutics Corp have been -127% over the past three years .

Back to Top